Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1396 (LINC01396) is a member of the long intergenic non-coding RNA (lincRNA) class, defined as a non-coding RNA transcript greater than 200 nucleotides in length that does not overlap with annotated protein-coding genes[1][5]. These molecules typically reside in the nucleus and may regulate gene transcription, chromatin state, and genome architecture, often with tissue specificity[5]. While many lincRNAs modulate cell functions such as proliferation or differentiation, there is currently no direct evidence that LINC01396 itself is involved in specific biological pathways, associated with disease, or considered a therapeutic target[1]. No drugs, clinical biomarkers, or established safety concerns are known for LINC01396 as of the current literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1396 (LINC01396).